Seagen faces criticism over 'problematic' executive compensation; Novo says oral Ozempic leads to 15% weight loss

Taking stock of the drug industry, from the lab to the medicine chest

May 22, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Seagen criticized by shareholder advisory firm for 'problematic' executive compensation ahead of Pfizer acquisition Glass Lewis believes Seagen's former CEO will get a "substantial windfall," including $46 million in golden parachute payments. By Ed Silverman STAT+ | Novo says oral version of Ozempic leads to 15% weight loss Semaglutide is already a blockbuster in injectable form as Wegovy and Ozempic. The data on a pill form could bolster demand even more. By Damian Garde STAT+ | In early trial, drug appears to reduce harmful protein buildup in heart An Astra Zeneca-licensed compound reversed some effects of ATTR-CM, a condition in which amyloid protein builds up in the heart. By Elaine Chen 'A textbook case of environmental racism': The battle over the Brookhaven Landfill The area of North Bellport on Long Island sits in the shadows of a massive landfill and has the lowest life expectancy on Long Island. By Nicholas St. Fleur

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser